Skip to main content

Table 8 COX regression analysis of prognostic factors affecting OS in SCLC ICIs-related myocarditis patients

From: Immune checkpoint inhibitor-related myocarditis in patients with lung cancer

Factors

Univariable

  

Hazard Ratio

(95% CI)

P Value

   

Age ≥ 70

0.9(0.18–4.17)

0.854

   

BMI ≥ 24

1.4(0.34–5.50)

0.656

   

Male gender

0.6(0.13–2.94)

0.535

   

Smoke

0.9(0.19–4.34)

0.890

   

Drink

1.7(0.42–6.75)

0.464

   

IV stage

22.0(0-6406832.19)

0.630

   

PD1

0.8(0.21–2.96)

0.730

   

Cardiovascular history

1.4(0.38–5.29)

0.603

   

Diabetes Mellitus

0.5(0.06–4.12)

0.532

   

PD-L1 express

0.1(0-0-13232.32)

0.630

   

Driving gene mutations

3.1(0.37–25.83)

0.295

   

History of radiotherapy

0.7(0.17–2.85)

0.630

   

Immunotherapy lines ≥ 2

2.2(0.54–8.68)

0.277

   

Concurrent other irAEs

0.8(0.20–2.83)

0.671

   

Glucocorticoids therapy

1.2(0.52–5.91)

0.801

   

immunotherapy cycles ≥ 2

0.1(0.03–0.48)

0.002

   

Grade of myocarditis > 2

5.0(0.56–44.6)

0.151

   
  1. BMI, body mass index; NSCLC, non-small cell lung cancer; PD-1, anti-programmed death-1; ICI, immune checkpoint inhibitors; irAEs, immune-related adverse events; PD-L1 express, anti-programmed death-ligand 1 express
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us